Mar 29, 2018
Indivior Enters Into an Exclusive Global License Agreement for C4X Discovery's Orexin-1 (OX1) Antagonist Program
Mar 21, 2018
Aptinyx to Present at Needham & Company's 17th Annual Healthcare Conference
Feb 07, 2018
Redefined Alzheimer's Biology Has Implications For Diagnostic Tools and Drug Design
Jan 31, 2018
A new publication confirms AZTherapies's innovative drug combination approach to address the neuroinflammation response via neuro-immunology and amyloid beta accumulation associated with neurodegeneration and Alzheimer's disease.
Dec 28, 2017
Aptinyx to Present at 36th Annual J.P. Morgan Healthcare Conference
Dec 18, 2017
Aptinyx Raises $70 Million in Series B Financing to Advance Growing Pipeline through Clinical Studies in Neurologic Disorders
Dec 07, 2017
Aptinyx Bolsters Executive Leadership Team with Appointment of Andy Kidd as Chief Commercial Officer
Nov 02, 2017
Amgen And Novartis Announce Expanded Collaboration With Banner Alzheimer's Institute In Pioneering Prevention Program
Nov 01, 2017
United Neuroscience Presents Data for Phase 2 Active Vaccine Program UB-311 at the Clinical Trials on Alzheimer's Disease 2017 Meeting
Oct 30, 2017
New Data Highlight Innovative Ways to Assess Patients with Early Alzheimer's Disease and Later Stage Alzheimer's Disease Dementia
Sep 21, 2017
Aptinyx to Present at Ladenburg Thalmann and Cantor Fitzgerald Healthcare Conferences
Aug 02, 2017
Beta-Secretase (BACE) Inhibitors Pipeline Analysis, 2017 - 15 Product Candidates in Different Stages of Development